Effect of landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): a case series

ESC Heart Fail. 2022 Feb;9(1):766-770. doi: 10.1002/ehf2.13763. Epub 2021 Dec 27.


Tachycardia and rapid tachyarrhythmias are common in acute clinical settings and may hasten the deterioration of haemodynamics in patients with acute decompensated heart failure (ADHF), treated with inotropes. The concomitant use of a short-acting β1-selective beta-blocker, such as landiolol, could rapidly and safely restore an adequate heart rate without any negative inotropic effect. We present a case series of five patients with left ventricular dysfunction, admitted to our Intensive Cardiac Care Unit with ADHF deteriorated to cardiogenic shock, treated with a combination of landiolol and inotropes. Landiolol was effective in terms of rate control and haemodynamics optimization, enabling de-escalation of catecholamine dosing in all patients. The infusion was always well tolerated without hypotension. In conclusion, a continuous infusion of a low dose of landiolol (3-16 mcg/kg/min) to manage tachycardia and ventricular or supraventricular tachyarrhythmias in haemodynamically unstable patients may be considered.

Keywords: Acute decompensated heart failure; Inotropes; Landiolol; Tachyarrhythmias; Tachycardia.

Publication types

  • Case Reports

MeSH terms

  • Heart Failure* / complications
  • Heart Failure* / drug therapy
  • Humans
  • Morpholines* / adverse effects
  • Morpholines* / therapeutic use
  • Tachycardia / chemically induced
  • Tachycardia / complications
  • Tachycardia / drug therapy
  • Urea / adverse effects
  • Urea / analogs & derivatives
  • Urea / therapeutic use


  • Morpholines
  • landiolol
  • Urea